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Introduction
Alterations in the local ECM architecture and composition usu-
ally accompany disease progression such as oncogenic transfor-
mation. One of the most abundant components of the ECM, the 
adhesive glycoprotein fi  bronectin (FN), is lost from the surface 
of many transformed cells (Hynes, 1990). FN functions pre-
dominantly within the context of a fi  brillar matrix, and changes 
in FN fi  bril assembly occur during tumor progression because 
of reduced expression and/or insuffi  cient binding to cell surface 
receptors. Reintroduction of FN into tumor cell cultures increases 
their adhesivity, restores a morphology characteristic of non-
transformed cells (Yamada et al., 1976; Ali et al., 1977; Pasqualini 
et al., 1996), and reestablishes a fi  brillar matrix (Schwarzbauer, 
1991). These observations illustrate the detrimental effects of 
loss of pericellular matrix and underscore the importance of FN 
expression and deposition into a fi  brillar ECM for mainte-
nance of normal tissue organization.
FN matrix assembly is a cell-mediated process, initiated 
as the integrin receptor α5β1 binds to the RGD sequence and 
synergy site on FN (Schwarzbauer and Sechler, 1999; Mao and 
Schwarzbauer, 2005). Clustering of integrin heterodimers 
brings molecules of FN in close proximity and promotes FN 
self-association. Inside the cell, adaptor proteins that interact 
with integrin cytoplasmic domains become juxtaposed and acti-
vate their downstream signaling partners, such as FAK and 
RhoA GTPase (Miranti and Brugge, 2002). Nascent FN fi  brils 
are formed between adjacent cells, and as matrix assembly pro-
gresses, these fi  brils form a meshwork that is characterized by 
its insolubility in deoxycholate (DOC) detergent (McKeown-
Longo and Mosher, 1983; Chen and Mosher, 1996). Although 
the major steps in matrix assembly have been well established, 
little information is available about the gene expression changes 
that accompany the acquisition of a DOC-insoluble matrix. 
The human fi  brosarcoma cell line HT1080 provides a useful 
model for FN matrix assembly because these cells do not assemble 
FN unless stimulated with the transcriptional regulator dexa-
methasone or the Ras pathway inhibitor PD98059 (McKeown-
Longo and Etzler, 1987; Brenner et al., 2000).
We have found that diastrophic dysplasia sulfate trans-
porter (DTDST), a sulfate/choride antiporter (Hastbacka et al., 
1994), is up-regulated upon induction of FN matrix assembly in 
HT1080 cells. Mutations in the human DTDST gene result in a set 
of autosomal recessive chondrodysplasias that range in severity 
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iastrophic dysplasia sulfate transporter (DTDST) 
is a sulfate/chloride antiporter whose function is 
impaired in several human chondrodysplasias. 
We show that DTDST is upregulated by dexamethasone 
stimulation of HT1080 ﬁ  brosarcoma cells and is required 
for ﬁ  bronectin (FN) extracellular matrix deposition by these 
cells. DTDST imports sulfate for the modiﬁ  cation of glycos-
aminoglycans. We ﬁ  nd that N-sulfation of these chains 
is important for FN matrix assembly and that sulfation of 
cell surface proteoglycans is reduced in the absence of 
DTDST. Of the candidate HT1080 cell surface proteo-
glycans, only loss of syndecan-2 compromises FN as-
sembly, as shown by syndecan-2 small interfering RNA 
knockdown. DTDST is both necessary and sufﬁ  cient to 
induce FN matrix assembly in HT1080 cells. Knockdown 
of DTDST ablates FN matrix, whereas its overexpression 
increases assembly without dexamethasone stimulation. 
These results identify a previously unrecognized regula-
tory pathway for matrix assembly via modulation of a 
sulfate transporter and proteoglycan sulfation. These data 
raise the possibility that FN assembly defects contribute 
to chondrodysplasias.
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(Superti-Furga et al., 1996; Haila et al., 2001; Karniski, 2001). 
Patients show gross skeletal defects, reduced cellular sulfate 
uptake, and cartilage proteoglycan undersulfation (Rossi et al., 
1998). Proteoglycans are characterized by a core protein modi-
fi  ed by a heterogeneous number of sulfated glycosaminoglycan 
(GAG) chains (Esko, 1991). GAG chains are crucial for many 
proteoglycan functions. For example, CHO cells defi  cient in 
xylosyltransferase (Esko et al., 1985), the enzyme responsible 
for the fi  rst step in heparan and chondroitin sulfate GAG chain 
synthesis, have reduced ability to assemble FN matrix (Chung 
and Erickson, 1997). Posttranslational addition of sulfate to 
GAG chains also has a functional role. Elimination of total sul-
fation using sodium chlorate abolished the coreceptor function 
of syndecan-4 with basic fi  broblast growth factor, thereby pre-
venting mitogenic signaling in Swiss 3T3 cells (Rapraeger et al., 
1991). Inhibition of sulfation in C6 glioma cells reduced adhe-
sion to collagen IV, laminin, and FN (Keller et al., 1989; Mendes 
de Aguiar et al., 2002). Here we show that GAG chain sulfation 
in HT1080 cells depends on DTDST and, through its role in 
maintenance of cell surface sulfate levels, DTDST is both nec-
essary and suffi  cient to stimulate FN matrix assembly.
Results
Up-regulation of DTDST correlates with 
FN matrix assembly
HT1080 human fi  brosarcoma cells assemble FN into a matrix 
only with stimulation by the glucocorticoid dexamethasone 
(Oliver et al., 1983; McKeown-Longo and Etzler, 1987), acti-
vation of cell surface integrins (Brenner et al., 2000), or in-
hibition of MAP/extracellular signal–related kinase signaling 
with PD98059 (Brenner et al., 2000). DTDST showed dramatic 
up-regulation in microarray experiments performed using RNA 
from HT1080 cells treated with dexamethasone or PD98059. 
Quantitative RT-PCR analyses confi  rmed the microarray re-
sults and revealed stimulation of DTDST expression in HT1080 
cells by dexamethasone at 6 and 20 h and PD98059 at 20 h of 
treatment (Fig. 1 A). In WI-38(VA13) cells, a transformed lung 
fi  broblast cell line that constitutively assembles an extensive 
FN matrix, DTDST expression changed less than 1.5-fold with 
both treatments at both time intervals. Thus, DTDST expres-
sion was increased concomitant with HT1080 cells estab-
lishing competence to assemble FN into a fibrillar matrix. 
Basal levels of DTDST expression differ between these two 
cell lines (Fig. 1 B). Mean relative expression of the transcript is 
 2.5-fold higher in assembly-competent WI-38(VA13) cells, 
implying that stimulation of DTDST expression in assembly-
defi  cient HT1080 cells may be necessary for suffi  cient levels 
of sulfate import.
DTDST is one of the sulfate transporters that shuttles extra-
cellular sulfate into the cell in exchange for chloride. Five Na
+-
independent sulfate/anion transporters have been identifi  ed in 
the human genome (Markovich, 2001). Four of the fi  ve sulfate 
transporters (h-Sat-1, Pat-1, DTDST, and Pendrin) are expressed 
to varying degrees by HT1080 cells (Fig. 1 C), but only DTDST 
was up-regulated by dexamethasone stimulation (Fig. 1 D).
Inhibition of sulfation ablates FN 
matrix assembly
Cells isolated from diastrophic dysplasia patients show reduced 
sulfate uptake and defective sulfation of GAG chains (Rossi 
et al., 1996; Superti-Furga et al., 1996). To determine whether 
sulfation is required for FN matrix assembly in HT1080 cells, 
we treated cells with sodium chlorate to block sulfate addition. 
Chlorate is a competitive inhibitor of ATP sulfurylase, one of 
the enzymes involved in generation of adenosine 3′-phosphate 
Figure 1.  Up-regulation of DTDST correlates with induction of 
FN matrix assembly. (A) RNA was isolated from HT1080 (HT) or 
WI-38(VA13) cells (WI-38), treated with 0.1 μM dexamethasone 
(Dex) or 2.5 μM PD98059 (PD) for 6 or 20 h. cDNA was pre-
pared using random hexamers and DTDST levels were deter-
mined by real-time RT-PCR. Each sample was normalized to a 
housekeeping gene, ubiquitin C, and fold stimulation relative to 
unstimulated cells was determined. (B) RNA from untreated 
HT1080 or WI-38(VA13) cells was used for quantitative RT-PCR 
to assess the relative DTDST expression level in each cell line. 
(C) Quantitative RT-PCR on RNA from untreated HT1080 cells 
was performed using primers for the ﬁ  ve human sulfate/anion 
transporters (down-regulated in adenoma [Dra-1], h-Sat, Pat-1, 
Pendrin, and DTDST). (D) RNA from HT1080 cells treated or not 
with dexamethasone for 6 h was used for real time RT-PCR using 
primer pairs for each of the sulfate transporters. Values were nor-
malized and fold stimulation was determined as in A. In all cases, 
the mean of three independent trials was calculated and the value 
is listed on each bar. Error bars represent standard deviation.DTDST AND FIBRONECTIN ASSEMBLY • GALANTE AND SCHWARZBAUER 1001
5′-sulfatophosphate, the universal sulfate donor to intracellular 
proteins and carbohydrate moieties (Klaassen and Boles, 1997). 
Moreover, chlorate treatment diminishes heparan sulfate sul-
fation by 92%, and these unsulfated GAG chains have a dra-
matically reduced affi  nity for FN (Keller et al., 1989). HT1080 
cells were treated for 48 h with sodium chlorate and matrix 
assembly was then stimulated with dexamethasone for 20 h. 
Chlorate treatment did not affect cell viability and did not alter 
cell morphology or spreading in response to FN. Immunofl  uores-
cence imaging of matrix on dexamethasone-stimulated chlorate-
treated cells revealed a decrease in FN fi  brils compared with 
buffer-treated cells (Fig. 2, A and B). Consistent with this, 
immunoblot analysis of DOC lysates showed a dramatic de-
crease in DOC-insoluble FN upon chlorate treatment (Fig. 2 C). 
Isolation of DOC-insoluble material from dexamethasone-
stimulated and chlorate-treated WI-38(VA13) cells revealed a simi-
lar, although less dramatic, inhibition of matrix formation 
(Fig. 2 C). Proteins, including FN, can be sulfated on tyrosine resi-
dues through the action of tyrosylprotein sulfotransferase (Lee and 
Huttner, 1983). Inhibition of tyrosylprotein sulfotransferase 
with 2-chloroadenosine, however, had no effect on FN matrix 
formation (unpublished data), indicating that the essential sul-
fation for matrix assembly is on moieties other than tyrosine.
FN has been implicated in the early stages of bone and 
cartilage formation during mesenchymal cell condensation and 
differentiation (Dessau et al., 1980; Mackie et al., 1987; Tavella 
et al., 1997). MRC-5 primary human fi  broblasts differentiate into 
osteoblastic cells when treated with dexamethasone or BMP-2 
(Almeida et al., 2001). To determine whether chlorate inhibition 
affected FN matrix assembly by cells that have the potential to 
become osteoblasts, DOC-insoluble material from chlorate-treated 
MRC-5 cells was analyzed and showed dramatic reduction 
compared with that in untreated cells (Fig. 2 C). These data show 
that sulfation plays an important role in FN matrix formation 
in assembly-competent WI-38(VA13) cells, in assembly-defi  cient 
HT1080 fi  brosarcoma cells, and in nononcogenic cells capable 
of bone differentiation.
FN assembly requires sulfated GAG chains
Cells isolated from DTD patients (Superti-Furga et al., 1996; 
Rossi et al., 1998) or from a DTDST mutant mouse model (Forlino 
et al., 2005) show reduced sulfate uptake, and the primary 
biochemical defect is undersulfation of proteoglycans (Rossi 
et al., 1998). However, characterization of proteoglycans from 
DTD patient fi  broblasts has revealed normal synthesis of core 
proteins and normal initiation and elongation of GAG chains 
(Rossi et al., 1996). To determine whether GAG chains or their 
sulfation play a role in FN matrix assembly by HT1080 cells, 
we used 4-methylumbelliferyl-β-D-xyloside, an inhibitor of 
GAG chain initiation (Fritz and Esko, 2001). Increasing con-
centrations of xylosides caused a dosage-dependent and statis-
tically signifi  cant decrease in dexamethasone-induced DOC-
insoluble FN matrix (Fig. 3 A). Treatment of BHK cells with 
200 μM xylosides did not reduce matrix assembly (Chung and 
Erickson, 1997). This concentration of xylosides is on the low 
end of our dosage response, so it is possible that treatment of these 
cells with higher concentrations may have an inhibitory effect. 
BHK cell matrix assembly was also less sensitive to inhibition 
by soluble heparin and required treatment with GAG chains 
purifi  ed from BHK cells themselves, supporting the idea that 
HT1080 and BHK cells have different sensitivities to inhibitors 
of matrix assembly.
HT1080 FN matrix was also reduced by the addition of 
soluble heparin to the culture medium (Fig. 3 B). GAG chains 
are multiply sulfated by N and O linkages (Esko, 1991). Unlike 
soluble sulfated heparin, addition of soluble N-desulfated or fully 
desulfated heparin did not block FN matrix assembly (Fig. 3 C). 
The inability of soluble desulfated heparin to signifi  cantly in-
hibit assembly indicates that sulfation is a critical modifi  cation 
for the function of GAG chains in this process.
Sulfation of cell surface molecules depends 
on DTDST
Metabolic labeling and cell fractionation experiments have 
shown that a signifi  cant proportion of total sulfated macro-
molecules is localized to the membrane fraction (Sjoberg and 
Malmstrom, 1982; Wang et al., 1999; Shworak, 2001). We found 
that the matrix assembly defect of chlorate-treated cells was not 
restored by HT1080 cell conditioned medium (unpublished data), 
indicating that cell-associated, rather than secreted, sulfated mole-
cules play a role in FN matrix assembly. To test the requirement for 
Figure 2.  Inhibition of sulfation ablates FN matrix assembly. HT1080 
cells plated on coverslips were control treated (A) or treated for 48 h with 
50 mM sodium chlorate (B), and 0.1 μM dexamethasone was added for the 
last 20 h. Cells were ﬁ  xed and stained with anti-FN monoclonal antibody 
HFN7.1. Bars, 50 μm. (C) DOC lysates were prepared from HT1080, 
WI-38(VA13) cells, or MRC-5 human embryonic ﬁ  broblasts (MRC), either un-
treated (Con) or treated with sodium chlorate (Chl) as in B. DOC-insoluble 
material proportional to either 10 μg (HT and WI) or 0.67 μg (MRC) of 
total protein was electrophoresed on a 5% polyacrylamide-SDS gel. FN was 
detected with HFN7.1 monoclonal antibody.JCB • VOLUME 179 • NUMBER 5 • 2007  1002
DTDST, its expression was knocked down by treatment with a 
DTDST siRNA SMARTpool or with individual oligonucleo tides 
from the pool. A signifi  cant reduction in transcript levels, nearly 
13-fold, was detected by quantitative RT-PCR, whereas the ex-
pression of FN and of the other sulfate/anion transporters 
showed only slight variations with DTDST siRNA treatment 
(Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb
.200707150/DC1). To determine the effect of DTDST knock-
down on sulfation of cell-associated molecules, biotinylated cell 
surface proteins from [
35S]sulfate-labeled cells were isolated and 
analyzed. Compared with control membranes, the amount of 
sulfated molecules from chlorate-treated cells was reduced a 
dramatic fi  vefold and from DTDST siRNA-treated cells, it was 
twofold lower (Fig. 4 A). SDS-PAGE of these proteins confi  rmed 
that the label was in a high molecular mass smear, indicative of 
GAG-bearing proteoglycans (Fig. 4 B). These results suggest an 
important role for this transporter in controlling levels of sulfated 
cell surface GAGs on HT1080 cells.
Knockdown of syndecan-2, but not of other 
proteoglycans, blocks FN matrix assembly
HT1080 cells express the cell surface proteoglycans syndecan-1, 
-2, and -4, glypican-1, and betaglycan as determined by quantita-
tive RT-PCR. Knockdown of each transmembrane proteoglycan 
using specifi  c siRNAs was effective at reducing both mRNA 
and protein levels (Fig. S2, A and B, avail  able at http://www
.jcb.org/cgi/content/full/jcb.200707150/DC1). Knockdown of 
syndecan-2 had a signifi  cant impact on matrix formation in both 
HT1080 and WI-38(VA13) cells (Fig. 5, A and B), but syndecan-2 
RNAi did not alter transcript levels of the other transmem-
brane proteoglycans (Fig. S2 C). Knockdown of syndecan-4, 
Figure 3.  Sulfated GAG chains contribute to FN matrix assembly. DOC-
insoluble material was isolated from HT1080 cells grown in medium con-
taining 0.1 μM dexamethasone plus the indicated treatments for 20 h. 
DOC-insoluble material proportional to 10 μg of total protein was resolved 
and FN was detected in immunoblots using HFN7.1 antibody (A–C, insets). 
Treatments included increasing amounts of 4-methyl-umbelliferyl-β-D-
xyloside (A), increasing concentrations of soluble heparin (B), or 250 μg/ml 
fully sulfated heparin (Hep), heparin that was N-desulfated ((-)N), or hepa-
rin that was entirely devoid of sulfate groups ((-)N, O). Con, cells treated 
with vehicle only. In all cases, values are percentages as compared with 
the respective controls and are normalized to GAPDH expression. *, P < 
0.04; **, P < 0.02. All error bars represent standard deviations based on 
the mean of three independent trials. 
Figure 4.  Cell surface–sulfated molecules are decreased in the absence of 
DTDST. (A) Cultures were stimulated with dexamethasone for 20 h and la-
beled for the ﬁ  nal 12 h with 50 μCi/ml [
35S]sulfate, cell surface proteins 
were biotinylated, and biotin-labeled molecules were isolated from whole 
cell lysates with streptavidin-agarose beads. Equal amounts of protein 
were counted, the means were calculated, and data are presented as per-
centages relative to control cells. Error bars are standard deviation based 
on the mean of three trials. *, P < 0.02. (B) Material eluted from strepta-
vidin beads was separated on a 4–20% gradient SDS gel and the dried gel 
was exposed to ﬁ  lm for 35 d. Molecular mass standards in kilodaltons 
are indicated on the left. Con, control; Chl, chlorate-treated; RNAi, DTDST 
siRNA-treated.DTDST AND FIBRONECTIN ASSEMBLY • GALANTE AND SCHWARZBAUER 1003
betaglycan, or glypican-1 consistently showed a modest increase 
in DOC-insoluble FN (Fig. 5, A and C), but this difference 
was not statistically signifi  cant (Fig. 5 B). Down-regulation of 
syndecan-1 induces a fi  broblastic phenotype (Kato et al., 1995), 
which fi  ts with the slight increase in FN matrix we observed with 
syndecan-1 siRNA treatment (unpublished data). Syndecan-2 
has been previously suggested to be an FN-binding proteoglycan 
(Itano et al., 1993, 1996), primarily via its three heparan sulfate 
GAG chains, and has been implicated in matrix assembly (Klass 
et al., 2000). Our results single out syndecan-2 as an important 
component of the FN assembly machinery in HT1080 cells.
Integrin α5β1 is the primary receptor for FN matrix as-
sembly by fi  broblasts (Wu et al., 1993). Activation of α5β1 is 
suffi  cient to stimulate matrix assembly by HT1080 cells (Brenner 
et al., 2000). We assessed the contributions of proteoglycans 
and integrins in this process by combining an anti-α5β1 function-
blocking antibody, BIIG2, with soluble fully sulfated heparin. 
DOC-insoluble matrix was reduced with either BIIG2 or solu-
ble heparin alone, but simultaneous inhibition of both integrin 
and GAG binding eliminated dexamethasone-induced matrix 
formation (Fig. 5 D). These results show that integrins work in 
cooperation with sulfated proteoglycans at the cell surface to 
mediate FN matrix assembly.
DTDST function is necessary and sufﬁ  cient 
to stimulate FN matrix assembly
The requirement for DTDST in FN assembly was demonstrated 
using siRNA knockdown of DTDST in dexamethasone-treated 
HT1080 cells. Reduced DTDST levels led to an obvious reduc-
tion in mature FN fi  brils by immunofl  uorescence (Fig. 6, A and B) 
and a quantitative decrease in the amount of DOC-insoluble 
FN in both HT1080 and WI-38(VA13) cells (Fig. 6, C–E). 
Therefore, DTDST expression is necessary to enhance FN fi  bril 
assembly by HT1080 cells and also contributes to matrix for-
mation by assembly-competent WI-38(VA13) cells.
Dexamethasone-induced DTDST expression in HT1080 
cells increases concomitantly with competence for FN matrix 
assembly. To determine whether DTDST overexpression was 
suffi  cient to induce assembly in the absence of dexametha-
sone treatment, we generated HT1080 cells expressing a trans-
lational fusion of DTDST cDNA with GFP under control of 
the cytomegalovirus promoter (HT/DTDST-GFP) or express-
ing the GFP vector alone (HT/GFP). DTDST-GFP localized 
to membrane ruffl  es (Fig. 7, C and D). This distribution differed 
from that of GFP alone (Fig. 7 B) and was signifi  cantly above 
background HT1080 autofl  uorescence (Fig. 7 A). No differ-
ences in cell morphol  ogy (Fig. 7, E and F) or endogenous FN 
secretion (not depicted) were observed between HT/GFP and 
HT/DTDST-GFP cells. Overexpression of DTDST-GFP in-
creased accumulation of DOC-insoluble matrix in the absence 
of dexamethasone treatment (Fig. 8 A). In three independent 
experiments, we observed at least 15-fold more DOC-insoluble 
FN with DTDST overexpression than in control HT/GFP cells. 
These results demonstrate that up-regulation of this sulfate 
transporter is suffi  cient to induce FN assembly by HT1080 
cells. Dexamethasone stimulation increased the amount of FN 
matrix in all cells but the effect was much more pronounced in 
Figure 5.  Syndecan-2 knockdown diminishes FN matrix assembly. 
(A) HT1080 or WI-38(VA13) cells transfected with control, syndecan-2 
(SDC2), or syndecan-4 (SDC4) siRNAs were dexamethasone stimulated, 
and FN levels in DOC-insoluble lysates proportional to 5 μg of total protein 
were analyzed with HFN7.1 antibody. (B) Immunoblots developed with 
ECL Plus reagent were used to quantify FN levels in samples that were nor-
malized to GAPDH. Control transfected samples were set at 100% and 
percentages of DOC-insoluble FN with syndecan-2 or -4 siRNA treatments 
are expressed relative to the control. Error bars represent standard devia-
tion from three independent experiments. *, P < 0.03. (C) DOC-insoluble 
lysates from HT1080 cells transfected with control, glypican-1 (GPN), or 
betaglycan (BGN) siRNAs were immunoblotted with HFN7.1 antibody. 
(D) Cells were pretreated with an integrin α5 function-blocking antibody, 
BIIG2, at 1:250 dilution, 100 μg/ml of soluble heparin, or both. FN levels 
in DOC-insoluble fractions from three independent trials were analyzed 
and quantiﬁ  ed as in B. *, P < 0.007 compared with control; **, P < 0.009 
compared with single treatments.JCB • VOLUME 179 • NUMBER 5 • 2007  1004
HT/DTDST-GFP cells compared with HT/GFP cells (Fig. 8 A). 
Furthermore, sulfated cell surface proteins were increased with 
DTDST-GFP overexpression (Fig. S3 A, available at http://
www.jcb.org/cgi/content/full/jcb.200707150/DC1) but up- or 
down-regulation of DTDST did not affect the level of syndecan-2 
protein (Fig. S3 B). Similar results were obtained with two 
different HT/DTDST-GFP cell clones.
To rescue the effects of DTDST siRNA, we exploited the 
fact that the DTDST-GFP construct lacks DTDST 3′ untranslated 
region (UTR) sequences and designed siRNA oligonucleo-
tides that target this region of the transcript. Treatment with these 
oligonucleotides should knock down endogenous DTDST ex-
pression, whereas the DTDST-GFP transcript would be resis-
tant to this inhibition. Three 3′ UTR siRNA oligonucleotides were 
transfected individually into HT/GFP and HT/DTDST-GFP 
cell lines and DOC-insoluble lysates were analyzed. All 3′ 
UTR oligonucleotides reduced FN matrix levels in HT/GFP 
cells to varying degrees (Fig. 8, B and C). In contrast, the HT/
DTDST-GFP cell line assembled FN matrix even in the presence 
of these oligonucleotides (Fig. 8, B and C). Therefore, expression of 
DTDST-GFP compensates for the RNAi-mediated knockdown 
of endogenous DTDST transcripts and rescues the defect in FN 
matrix assembly. Collectively, our results demonstrate that DTDST 
expression is both necessary and sufficient to enhance FN 
Figure 6.  DTDST expression is necessary to stimulate FN matrix assembly. 
HT1080 cells were transfected with control siRNA oligonucleotides (A) or 
DTDST siRNAs (RNAi; B) and stimulated with 0.1 μM dexamethasone. 
After 48 h, cells were ﬁ  xed and stained with anti-FN HFN7.1 monoclonal anti-
body. Scale bars represent 20 μm. DOC-insoluble material from HT1080 
(C) or WI-38(VA13) (D) cells transfected with siCONTROL or DTDST siRNA 
was immunoblotted with HFN7.1 antibody. (E) DOC-insoluble material 
from three independent trials was immunoblotted and developed with ECL 
Plus. Values represent percent of FN signal relative to the control condition 
for each cell line. Error bars represent standard deviation. *, P < 0.04.
Figure 7.  A DTDST-GFP fusion protein localizes to the plasma membrane. 
HT1080 cells were mock transfected (A) or stably transfected with either 
pEGFP-N1 vector (B) or pEGFP-N1/DTDST (C and D). Live cells were 
stained with DRAQ5 and plated onto glass-bottom culture dishes for confo-
cal imaging. Images in A–C were captured with a zoom factor of three. 
(D) Image of live HT/DTDST-GFP cells (as in C) was collected with a zoom 
factor of 1. Bars, 20 μm. HT/GFP (E) and HT/DTDST-GFP (F) cells on FN-
coated coverslips were ﬁ  xed, permeabilized, and stained with rhodamine-
phalloidin and DAPI to visualize cell shapes.DTDST AND FIBRONECTIN ASSEMBLY • GALANTE AND SCHWARZBAUER 1005
matrix assembly through a process that depends on production 
of sulfated HT1080 cell surface proteins.
Discussion
We have identifi  ed an important regulatory role for the sulfate/
chloride antiporter DTDST in FN matrix assembly. DTDST gene 
expression increases signifi  cantly under conditions that promote 
matrix formation. RNAi knockdown and enforced expression of 
DTDST had opposite effects on FN matrix levels, indicating that 
this transporter is both necessary and suffi  cient to enhance 
HT1080 matrix assembly. GAG chains are known to participate 
in cell–FN interactions, but our results show that GAG chain sul-
fation also affects these interactions. Furthermore, knockdown of 
DTDST reduced cell surface sulfate levels, reinforcing the notion 
that DTDST functions to provide suffi  cient intracellular sulfate 
to maintain sulfated GAGs at the cell surface. Of the known 
membrane-associated proteoglycans on HT1080 cells, syndecan-2 
is the only one involved in the stimulation of FN assembly. 
Therefore, regulation of DTDST expression and sulfate transport 
provides a novel mechanism to modulate levels of matrix assem-
bly through sulfation of cell surface molecules.
Although there are several ways to obtain intracellular 
sulfate, cells rely primarily on active transport mechanisms for 
intracellular sulfate homeostasis (Markovich, 2001). Of the fi  ve 
known sulfate/anion transporters in humans, DTDST is the 
most ubiquitous and was the only one up-regulated in condi-
tions that induced FN matrix assembly in HT1080 cells. DTDST 
is integral for the maintenance of physiological sulfate levels. 
Cartilage from human DTD patients or a mouse knockin mutant 
model has low staining with alcian blue and toluidine blue (Rossi 
et al., 1996, 1998; Forlino et al., 2005), which are both cationic 
dyes with an affinity for negatively charged sulfate groups 
(Karlsson and Bjornsson, 2001). Undersulfation was confi  rmed 
by analyses of isolated cartilage proteoglycans. The extent of this 
undersulfation varied with the clinical severity of the disorder 
(Karniski, 2001), indicating a direct connection between DTDST 
function and sulfation of proteoglycans.
DTDST is expressed in a wide range of tissues including 
colon, various glands, pancreas, and kidney, among others (Haila 
et al., 2001). The most notable defects in DTD patients, however, 
are in cartilage architecture because of the high sulfate demand 
of this tissue. Fibroblasts isolated from these patients also show 
reduced activity in sulfate uptake assays and a high resistance to 
chromate, which is lethal to cells only when it is imported via 
functional sulfate transporters (Rossi et al., 1996). Although there 
are several different mutations so far identifi  ed in the human 
DTDST gene (Superti-Furga et al., 1996; Karniski, 2001), 
changes in activity of this transporter have not previously been 
linked to altered behaviors of tumor cells. There is precedent for 
down-regulation of other sulfate transporters in cancer. Down-
regulated in adenoma, a mammalian sulfate/chloride antiporter 
expressed exclusively in the colon, was isolated by subtractive 
hybridization comparing normal colon with colon carcinoma cells 
(Schweinfest et al., 1993), and reduced levels of pendrin have been 
reported in thyroid carcinoma (Bidart et al., 2000). Furthermore, 
reduced amounts and sulfation of heparan sulfate proteoglycans 
have been observed in SV40-transformed cells (Winterbourne 
and Mora, 1981), HT1080 fi  brosarcoma cells (Timar and Paterson, 
1990), E1A immortalized rat intestinal cells (Levy et al., 1990), 
and transformed rat kidney cells (Romaris et al., 1994). There-
fore, sulfate import may be necessary for maintenance of a nor-
mal, nontransformed phenotype, possibly through regulation of 
cell surface proteoglycans and FN matrix.
In chondrodysplasia patients as well as in the mouse model 
of DTD, proteoglycan sulfation was signifi  cantly reduced by mu-
tations in DTDST. In general, of the total intracellular sulfate con-
tent, more than two thirds is consumed by the sulfation of GAG 
chains (Shworak, 2001). These molecules would therefore be most 
dramatically affected by a defi  ciency in sulfate import. It has been 
shown that some cells localize 70% of total 
35SO4-labeled hepa-
ran sulfate chains to the plasma membrane (Wang et al., 1999). 
Figure 8.  Overexpression of DTDST is sufﬁ  cient to stimulate FN matrix 
assembly in the absence of dexamethasone. (A) HT/DTDST-GFP (DTDST) or 
HT-GFP (GFP) cells were stimulated, or not, with 0.1 μM dexamethasone 
as indicated. FN was detected in DOC-insoluble fractions using HFN7.1 
antibody. Blot is representative of three independent experiments on a 
single transfectant and similar results were obtained with two other cell 
clones. (B) HT/GFP (top) or HT/DTDST-GFP (bottom) cells stimulated with 
dexamethasone were treated with siRNAs directed against three remote 
locations within the 3′ UTR of endogenous DTDST (3128, 6158, and 3548). 
DOC-insoluble material was analyzed and the immunoblots are represen-
tative of three independent trials. (C) DOC-insoluble FN amounts were 
normalized to siCONTROL-transfected amounts (set at 100) from either HT/GFP 
or HT/DTDST-GFP cells. Error bars represent standard deviation. *, P < 0.02 
for comparison of two cell lines treated with the same oligonucleotide.JCB • VOLUME 179 • NUMBER 5 • 2007  1006
Defi  ciencies in sulfate import would therefore primarily affect 
sulfated GAGs at the cell surface and this, in fact, fi  ts with 
what we observed with chlorate or DTDST RNAi treatment. 
An important role for DTDST in GAG sulfation is further 
supported by the enhanced cell surface sulfate content in overex-
pressing cells.
Our fi  nding that syndecan-2 is important for matrix as-
sembly by HT1080 cells supports previous work that showed 
that a truncated form of this proteoglycan had a dominant- negative 
effect on deposition of FN and laminin during ECM assembly 
by CHO cell transfectants (Klass et al., 2000). Syndecans bind 
to the HepII domain of FN via electrostatic interactions me-
diated by heparan sulfate chains (Itano et al., 1993; Busby et al., 
1995). Syndecan-4 has been shown to work with integrins for 
full cell spreading and focal adhesion formation (Woods and 
Couchman, 1994; Saoncella et al., 1999; Midwood et al., 2004). 
Thus, it was somewhat surprising that syndecan-4 RNAi did not 
inhibit matrix assembly and, in fact, seemed to promote a mod-
est increase in matrix levels. One possible explanation for this 
difference is that syndecan-2 and -4 cytoplasmic tails interact 
with different effectors that potentially have distinct roles in cell 
adhesion and FN assembly. In that case, knockdown of expres-
sion of syndecan-4 would reduce competition between these 
proteoglycans for binding to the HepII site, allowing increased 
syndecan-2 engagement by FN and enhancing its associated 
intracellular signaling and matrix assembly. This explanation 
would also suggest that the relative proportions of proteo-
glycans, rather than their absolute levels, affect cell phenotypes. 
Glypican-1 reportedly also interacts with the HepII domain on 
FN (Tumova et al., 2000). Therefore, it is conceivable that in-
creased FN matrix in the absence of glypican-1, and possibly 
also betaglycan, could result from a similar loss of a competi-
tive inhibitor that can bind to a common site on FN.
Because FN matrix assembly is induced by up-regulation 
of DTDST and the downstream effects on proteoglycan sulfation 
and function, is it possible that perturbation of this process is 
an underlying cause of the skeletal defects in patients with DTD-
related chondrodysplasias? FN is a major component of the 
chondrocyte microenvironment during cartilage development 
(Hedman et al., 1982; Poole et al., 1992) and, in adult tissue, 
colocalizes with some forms of collagen (Chang et al., 1997). 
Pericellular FN likely promotes chondrocyte adhesion and inter-
acts with cell surface sulfated proteoglycans, which may be es-
sential for initial deposition of ECM. Collagen fi  bril formation is 
dependent on the presence of FN matrix in some cell types (Velling 
et al., 2002), and FN is replaced by a more collagen-rich matrix 
during cartilage differentiation (Dessau et al., 1978; Dessau 
et al., 1980, 1981), raising the possibility that FN matrix may 
present a framework for collagen deposition during mesenchyme 
condensation and cartilage development. β1 integrin receptors 
for collagen and FN are expressed in chondrocytes, and β1-null 
chondrocytes are defective in skeletal development with reduced 
adhesion on collagen II and FN and development of chondro-
dysplasias (Aszodi et al., 2003). Clearly, there is interdepen-
dence between assembly of FN and collagen matrices and 
integrin–ECM interactions in cartilage formation. FN has also 
been detected in the ossifi  cation centers and growth plates of 
developing and mature bones (Nordahl et al., 1995; unpublished 
data) and has been implicated in early events in osteogenesis, 
where it is thought to promote osteoblast adhesion (Mackie 
et al., 1987; Moursi et al., 1996). Evidence supporting a role for 
FN matrix in differentiation of cartilage and bone, along with 
our data on the reduction of FN matrix in the absence of DTDST 
expression, provides an intriguing explanation for the skeletal 
defects observed in the diastrophic dysplasias.
Materials and methods
Cell culture
HT1080, WI-38(VA13), and MRC-5 cells (from T. Shenk, Princeton Uni-
versity, Princeton, NJ) were grown in DME with 10% FBS (Thermo Fisher 
Scientiﬁ  c) and antibiotic–antimycotic cocktail (Invitrogen). For experiments 
in low sulfate conditions, cells were grown in Ham’s F12 (Invitrogen) with 
10% PBS-dialyzed FBS and no sulfate salt–containing antibiotics.
Construction of a DTDST-overexpressing cell line (HT/DTDST-GFP)
PCR was performed to generate XhoI and XmaI sites ﬂ  anking DTDST cDNA 
from the pGEMHE-DTD plasmid (from L. Karniski, University of Iowa, Iowa 
City, IA) using the primers 5′-A  T  T  C  C  T  C  T  C  G  A  G  C  T  G  T  C  G  G  C  G  C  C  G  C  G  -3′ 
and 5′-C  C  A  G  T  T  C  C  C  G  G  G  T  T  C  C  -G  C  T  T  C  C  G  C  T  T  C  C  A  T  C  A  C  T  A  C  T  A  A  G  A  C  T-
C  A  G  A  C  C  A  T  T  G  G  C  -3′ and Elongase DNA polymerase (Invitrogen) under 
the following conditions for 25 cycles: 94°C for 1.5 min, 52°C for 1 min, 
and 68°C for 3 min. pEGFP-N1 (BD Biosciences; Clontech Laboratories, Inc.) 
was digested and ligated to the XhoI–XmaI PCR product to generate 
pEGFPN1/DTDST with GFP cDNA fused at the 3′ end of DTDST cDNA. 4 μg 
pEGFPN1/DTDST DNA or the corresponding empty vector was transfected 
into HT1080 cells using Lipofectamine 2000 (Invitrogen). Individual clones 
were selected with 1 mg/ml geneticin sulfate (Invitrogen) and serially ex-
panded until stable cell lines expressing the construct or carrying the empty 
vector were established. Five clones were expanded with DTDST expres-
sion levels that ranged between 4.8- and 16-fold above HT1080 cells car-
rying the empty vector (HT/GFP), as determined by quantitative RT-PCR. 
The three highest expressors with levels at 9.8-, 10.5-, and 16-fold above 
control clones were analyzed for matrix assembly.
Real time RT-PCR
RNA from subconﬂ  uent cells was isolated using the Trizol reagent (Invitro-
gen) according to the manufacturer’s instructions. cDNA was made from 
the isolated RNA template using Superscript II Reverse transcriptase, 2.5 mM 
of random hexamer mix, and 1 μg of total RNA. The reverse transcription 
reaction was performed with the following conditions: 37°C for 60 min, 
99°C for 5 min, and 5°C for 5 min. The SYBR Green PCR Master Mix 
(Applied Biosystems) was used with 800 nM of each primer. The real-time 
reaction was done in triplicate in an ABI Prism 7900 HT detection system 
(Applied Biosystems) using the following reaction proﬁ  le: 2 min at 50°C 
and 10 min at 95°C for one cycle, followed by 15 s at 95°C and 1 min at 
60°C for 40 cycles. SDS 2.1 software (Applied Biosystems) was used to 
plot the standard curve and to determine the relative expression levels of 
each mRNA. Values for each experimental condition were normalized to 
the level of ubiquitin C in a parallel RNA sample.
Metabolic labeling and cell surface biotinylation
Cells were lifted in versene (Invitrogen) and 6 × 10
5 cells per well were 
plated in 6-well plates. After attachment, the medium was replaced with 
Ham’s F12 low sulfate medium plus any treatments as indicated. Na2-[
35S]-
SO4 (MP Biomedicals) was reconstituted in water. 50 μCi/ml was added 
to each well and cells were labeled for 12 h.
Cultures were washed thoroughly with cold PBS and incubated for 
30 min at 4°C with 1mg/ml Sulfo-NHS-LC-Biotin (Thermo Fisher Scientiﬁ  c). 
Biotinylation reactions were quenched with ﬁ  ve washes of 50 mM NH4Cl 
in PBS. Cells were lysed using radioimmunoprecipitation assay buffer (50 mM 
Hepes, pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1% Triton X-100, 1% sodium 
deoxycholate, 0.1% SDS, 1 mM EGTA, 100 U/ml aprotinin, 10 μg/ml 
leupeptin, and 1 mM PMSF). Streptavidin immobilized on 6% agarose beads 
was washed and resuspended in binding buffer (0.1% SDS in PBS). 100 μl of 
the 50% slurry was added to 200 μl of whole cell lysate. Samples were incu-
bated for 2 h with rotation at 4°C. Streptavidin beads were washed ﬁ  ve 
times with binding buffer and boiled for 5 min in SDS sample buffer (2% SDS, 
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Aliquots were removed before the addition of 2-mercaptoethanol to deter-
mine total protein concentration by bicinchoninic acid assay (Thermo 
Fisher Scientiﬁ  c). Equivalent amounts of total protein were counted in a 
liquid scintillation counter (TriCarb 2800TR; PerkinElmer), and mean counts 
per minute were obtained over 20-min periods. Material eluted from strepta-
vidin beads was separated on a 4–20% gradient SDS gel. The dried gel was 
exposed to ﬁ  lm for 35 d.
Pretreatments
Cells were pretreated with various agents in normal growth media and 25 mM 
Hepes, pH 7.2, for 30 min with tumbling at 37°C. Treatments included 50 mM 
sodium chlorate (Sigma-Aldrich), 4-methylumbelliferyl-β-D-xyloside (Sigma-
Aldrich), and soluble heparin or chondroitin sulfate-A (Sigma-Aldrich). 
Concentrations are indicated in the ﬁ  gure legends. For sulfation pattern 
experiments, cells were incubated with 250 μg/ml N-acetyl-de-O-sulfated 
heparin or de-N-sulfated heparin (Sigma-Aldrich). For α5β1 integrin block-
ing experiments, cells were allowed to adhere to tissue culture plates for 2 h. 
The medium was then replaced with anti-α5 integrin monoclonal antibody 
BIIG2 at a 1:250 dilution (obtained from C.H. Damsky, University of Cali-
fornia, San Francisco, San Francisco, CA). After the 30-min preincubation, 
cells were stimulated with 0.1 μM dexamethasone and plated onto tissue 
culture plates. In all cases, after 20 h of dexamethasone stimulation, DOC 
lysates were harvested.
Immunoﬂ  uorescence
For matrix assembly experiments, 6 × 10
5 cells per well were seeded onto 
6-well tissue culture plates and allowed to attach and spread on glass cover-
slips with dexamethasone for 20 h. Cells were ﬁ  xed in 3.7% formaldehyde 
in PBS plus 0.5 mM MgCl2 for 15 min. Samples were incubated with anti–
human FN monoclonal antibody HFN7.1 (Developmental Studies Hybrid-
oma Bank) at a 1:100 dilution in 2% ovalbumin (Sigma-Aldrich) in PBS for 
30 min at 37°C, followed by a 1:600 dilution of ﬂ  uorescein-conjugated 
goat anti–mouse secondary antibody (Invitrogen). Images were acquired 
on a microscope (Eclipse TE2000-U; Nikon) with 2,000-ms exposure times. 
Brightness was adjusted to +8 and contrast to +48 in Photoshop (Adobe). 
To analyze cell shapes, cells were allowed to attach and spread on FN-
coated coverslips for 20 h, and then were ﬁ  xed, permeabilized with 0.5% 
NP-40 (EMD), and stained with DAPI (Invitrogen) at a 1:1,000 dilution to 
visualize nuclei and a 1:1,000 dilution of rhodamine-phalloidin (Invitro-
gen) for actin ﬁ  laments. Images were acquired with a 20×/0.45 objective. 
Image brightness/contrast was adjusted in Photoshop to +2/+54 and 
+31/+24 for HT/GFP and HT/DTDST-GFP, respectively. For live confocal 
image acquisition, cells were stained with DRAQ5 (Qbiogene) at a ﬁ  nal 
concentration of 5 μM for 30 min at 37°C, and then plated onto glass-
bottom culture dishes (MatTek) for confocal analysis. All confocal images 
were captured on a confocal system (LSM 510; Carl Zeiss, Inc.) using a 
water immersion objective (C-Apochromat 40× 1.2 NA; Nikon) and 
LSM 510 software (version 3.2). Brightness and contrast for images col-
lected at zoom factor 3 were identically modiﬁ  ed in Photoshop to +22. 
Images collected at zoom factor 1 were adjusted in Photoshop to +22 
brightness and +18 contrast.
DOC insolubility assay and immunoblotting
Cells were plated onto 6-well dishes, pretreated as indicated, and stimu-
lated with dexamethasone for 20 h. After this period, DOC-soluble and 
-insoluble fractions were prepared as described previously (Sechler et al., 
1996). Volumes were scaled up accordingly based on the surface area of 
the dish. Protein concentrations of DOC-soluble fractions were determined 
using the bicinchoninic acid assay, and amounts of DOC-insoluble material 
proportional to 5 or 10 μg of DOC-soluble material were run on a 5% 
polyacrylamide-SDS gel, transferred to a nitrocellulose membrane (GE 
Healthcare), and blocked in 25 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 
0.1% Tween-20. Human FN was detected using HFN7.1 antibody at 
1:300 dilution in the blocking buffer, and anti-GAPDH (ab9484; Abcam) 
was used at 1:10,000 dilution. Goat anti–mouse conjugated to HRP (Thermo 
Fisher Scientiﬁ  c) was used as a secondary antibody at 1:10,000. Blots from 
three independent trials were developed using the ECL reagent (Thermo 
Fisher Scientiﬁ  c). When quantiﬁ  cation was necessary, blots were devel-
oped using ECL Plus Western Detection System GE Healthcare), a scanner 
(STORM 860; GE Healthcare), and ImageQuant TL v2005.04 software 
(GE Healthcare). Values were normalized to GAPDH levels.
Normalization and statistics
Quantitative RT-PCR was performed in triplicate for each RNA preparation. 
Raw values were averaged and normalized to the mean value for ubiquitin C. 
Experimental values were then divided by control values to give a fold 
change. To express values as a percent, the control value was set at 100%. 
All error bars represent standard deviations based on the mean of three in-
dependent trials. Probability of a signiﬁ  cant difference between two values 
was determined by a paired, two-tailed Student’s t test. Values were con-
sidered to be statistically signiﬁ  cant when P < 0.05.
siRNA treatment
Cells were trypsinized and 1.8 × 10
5 cells were plated in 6-well tissue cul-
ture dishes in DME and 10% FBS without antibiotics. After 24 h, 100 nM 
SMARTPOOL siRNAs (Dharmacon, Inc.) for DTDST or individual proteogly-
cans were transfected as described in the Lipofectamine RNAiMAX protocol 
(Invitrogen). This procedure was also used with each individual siRNA 
oligonucleotide at 100 nM (coding region siRNAs: 800, 1263, 1824, 
2124; 3′ UTR siRNAs: 3128, 6158, 3548 [all are named for the ﬁ  rst base 
position in the DTDST cDNA]). The siCONTROL nontargeting siRNA pool 
composed of four oligonucleotides experimentally shown not to target mam-
malian RNAs was transfected in parallel. 24 h after transfection, cells were 
trypsinized and replated at 6 × 10
5 cells with 0.1 μM dexamethasone.
Detection of proteoglycans by immunoblotting
A procedure provided by A. Rapraeger (University of Wisconsin Medical 
School, Madison, WI) was used. Whole cell lysates were prepared using 
radioimmunoprecipitation assay buffer (50 mM Hepes, pH 7.5, 150 mM 
NaCl, 1.5 mM MgCl2, 1% Triton X-100, 1% sodium deoxycholate, 0.1% 
SDS, and a protease inhibitor cocktail). Lysates were methanol precipitated 
overnight at −20°C. Samples were spun at 14,000 rpm for 5 min at 4°C 
and 1 vol of 100% chilled acetone was added. Lyophilized GAGase en-
zymes were reconstituted in PBS containing 10
−5 M CaCl2 and MgCl2, 
1 g/liter glucose, and 1 mg/ml BSA. For GAGase treatment, pellets were 
resuspended in heparitinase I buffer (50 mM Hepes, pH 6.5, 50 mM sodium 
acetate, 150 mM NaCl, and 5 mM CaCl2). Heparitinase I (Seikagaku Inc.) 
at a ﬁ   nal concentration of 2.4 × 10
−3 IU/ml and chondroitinase ABC 
(Sigma-Aldrich) at a ﬁ  nal concentration of 0.1 U/ml were added to each 
sample. Samples were incubated at 37°C for 2 h, and then 1 μl of fresh 
enzyme was added and the 2-h incubation was repeated. Reactions were 
stopped with the addition of electrophoresis sample buffer. Proteins were 
transferred to a methanol prewetted Immobilon-P polyvinylidene ﬂ  uoride 
membrane (Millipore). Blots were ﬁ  xed in 0.25% glutaraldehyde for 30 min, 
rinsed several times in distilled H2O, rinsed in TBS (50 mM Tris-HCl, pH 
7.5, and 200 mM NaCl), and blocked in TBS with 3% BSA. Blots were 
hybridized with 3G10 anti–heparan sulfate delta antibody (Seikagaku 
Inc.) at a dilution of 1:3,000, washed with TBS + 0.1% Tween-20 (Sigma-
Aldrich), and treated with a 1:10,000 dilution of goat anti–mouse HRP 
secondary antibody.
Online supplemental material
Fig. S1 shows the effects of DTDST siRNA treatment on mRNA expression 
levels of the other sulfate transporters. Fig. S2 (A and B) shows knockdown 
of individual proteoglycan mRNAs and reduced protein levels with speciﬁ  c 
siRNA treatments, and Fig. S2 C shows that syndecan-2 mRNA levels, but 
not levels of other proteoglycan mRNAs, are affected by syndecan-2 siRNA 
treatment. Fig. S3 shows increased cell surface sulfate levels with DTDST 
overexpression and no effect of DTDST knockdown or overexpression on 
syndecan-2 protein levels. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200707150/DC1.
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